Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott’s Recommitment To Core Diagnostics Is Rewarded By Strong Returns

This article was originally published in The Gray Sheet

Executive Summary

Abbott has a newfound loyalty to its long-struggling core diagnostics business, which the company was at the brink of unloading just last year, and the division has responded with a dramatic turnaround
Advertisement

Related Content

FDA Warning Letter Cites Quality Control Issues At Abbott Diabetes Care
FDA Warning Letter Cites Quality Control Issues At Abbott Diabetes Care
A Compliant Abbott Channels More Funds Into Core Diagnostics R&D
A Compliant Abbott Channels More Funds Into Core Diagnostics R&D
Abbott’s New Diagnostics Chief Confident In A Future Without GE
GE And Abbott Walk Away From $8 Billion Diagnostics Deal
GE And Abbott Walk Away From $8 Billion Diagnostics Deal
Abbott’s Lake County Plant Gets FDA Nod; Prism Squares Up For U.S. Debut
Advertisement
UsernamePublicRestriction

Register

MT026395

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel